Pramlintide

Last Updated: August 2026

Pramlintide is a synthetic analog of amylin, the pancreatic beta-cell hormone co-secreted with insulin. It substitutes proline at positions 25, 28, and 29 to prevent the aggregation that makes native amylin impractical as a drug.1 source It is FDA-approved as Symlin® (subcutaneous, as a mealtime adjunct to insulin in type 1 and type 2 diabetes) — making it one of the few compounds in this catalog with a full human approval and safety record. In the research market it is sold for research use only.

What is Pramlintide and why does the amylin mechanism matter?

Pramlintide reproduces amylin's three complementary actions — suppressing glucagon secretion, slowing gastric emptying, and increasing satiety — which together blunt post-meal glucose spikes and reduce food intake. This is a distinct and complementary axis to the GLP-1 class: where semaglutide and retatrutide act on incretin receptors, pramlintide acts on amylin receptors. It is the clinical predecessor to the longer-acting amylin analog cagrilintide now studied for obesity. Evidence level: FDA-approved (human clinical pharmacology).

What does the clinical evidence show?

Pramlintide has a full body of human clinical evidence — it is FDA-approved, with randomized trials showing improved glycemic control (lower HbA1c and post-prandial glucose) and modest weight loss as an insulin adjunct — in the label's pivotal 6-month data, placebo-corrected HbA1c reductions of roughly 0.25–0.34 percentage points, with weight falling about 0.8–1.6 kg (type 1) and 1.4–1.6 kg (type 2, 120 mcg) while placebo groups gained weight1 source — real but small effects next to the incretin drugs. This distinguishes it sharply from the investigational compounds it sits beside. Evidence level: FDA-approved (human RCTs). Its established profile also means its risks are well characterized (below).

What are the documented side effects of Pramlintide?

The principal documented risk is severe hypoglycemia when combined with insulin — a boxed warning on the US label, occurring particularly in patients with type 1 diabetes and, when it occurs, seen within 3 hours after a SYMLIN injection (the label directs a 50% reduction of mealtime insulin doses when starting), driven by its glucose-lowering action; nausea is the most common non-serious effect, especially early in use — in type 1 diabetes trials, nausea occurred in 48% on pramlintide vs 17% on placebo.1 source Because it is approved, these are established from controlled data rather than extrapolated. Evidence level: FDA-approved labeling. It is administered as a separate subcutaneous injection from insulin.1 source

What is the regulatory status of Pramlintide?

Pramlintide is FDA-approved as Symlin (initial US approval 2005) for use with mealtime insulin1 source — but products sold through research-chemical vendors are not the approved pharmaceutical and are marketed for research use only. As of August 2026 pramlintide remains the only approved amylin-analog drug in the US: the long-acting amylin analog cagrilintide is investigational, and the CagriSema (cagrilintide + semaglutide) NDA — filed December 18, 2025 — had not been approved as of August 2026.1 source That distinction matters for purity and provenance. Verify local rules via the legal status guide.

Why does vendor verification matter, and how does Peptigrity verify?

Because research-market pramlintide is not the approved product, HPLC purity and mass-spec identity (expected MW ~3949 Da) are the objective checks that a vial contains the correct amylin analog at the labeled amount.1 source Peptigrity collects independent third-party Certificates of Analysis for pramlintide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The trust score weights lab purity and reviews equally (50/50). Compare any vendor claim against the independent pramlintide lab tests on file. See how to read lab results.

This section is for educational and informational purposes only and does not constitute medical advice. Research-grade pramlintide sold for laboratory use is not an FDA-approved product. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.